Pros/Cons of Routine Screening: Early Prostate Cancer Diagnoses Continue To Fall

September 17, 2016

Diagnoses of early prostate cancer continue to decline. In 2012, the U.S. Preventive Services Task Force recommended against routine screening for prostate cancer using a blood test to check the level of PSA (prostate specific antigen) in male patients. PSA is a protein produced by the prostate gland. The test can reveal when prostate cancer exists, but it also has a high “false positive” rate. This means patients who do not have prostate cancer may be subjected to unnecessary anxiety and follow-up tests. However, some experts worry that by stopping the routine screening, fewer patients who do have prostate cancer are being diagnosed while the cancer is still in the early stages. In its early stages, prostate cancer is easier to teat with a high success rate. Read more about the pros and cons of routine prostate cancer screening here.

To learn more about how prostate cancer is diagnosed, visit My PearlPoint.